* age \<18 years old * pregnant or breast feeding * inability to take oral medication * inability to provide informed written consent * known hypersensitivity towards 4-aminoquinolines, e.g. hydroxychloroquine and/or camostat * use of hydroxychloroquine, chloroquine and or camostat within 6 months prior to baseline * patients with known retinopathy or macular degeneration patients with known glucose-6-phosphate dehydrogenase (g6pd) deficiency * prolonged qtc-interval in baseline ecg (\>500 ms) * concomitant medication associated with qtc-interval prolongation, which cannot be withdrawn prior to study drug administration * major comorbidities, possibly leading to increased unwanted side effects of study drugs:

* age \<18 years old * pregnant or breast feeding * inability to take oral medication * inability to provide informed written consent * known hypersensitivity towards 4-aminoquinolines, e.g. hydroxychloroquine and/or camostat * use of hydroxychloroquine, chloroquine and or camostat within 6 months prior to baseline * patients with known retinopathy or macular degeneration patients with known glucose-6-phosphate dehydrogenase (g6pd) deficiency * prolonged qtc-interval in baseline ecg (\>500 ms) * concomitant medication associated with qtc-interval prolongation, which cannot be withdrawn prior to study drug administration * major comorbidities, possibly leading to increased unwanted side effects of study drugs:

- age <18 years old - pregnant or breast feeding - inability to take oral medication - inability to provide informed written consent - known hypersensitivity towards 4-aminoquinolines, e.g. hydroxychloroquine and/or camostat - use of hydroxychloroquine, chloroquine and or camostat within 6 months prior to baseline - patients with known retinopathy or macular degeneration patients with known glucose-6-phosphate dehydrogenase (g6pd) deficiency - prolonged qtc-interval in baseline ecg (>500 ms) - concomitant medication associated with qtc-interval prolongation, which cannot be withdrawn prior to study drug administration - major comorbidities, possibly leading to increased unwanted side effects of study drugs:

- age <18 years old - pregnant or breast feeding - inability to take oral medication - inability to provide informed written consent - known hypersensitivity towards 4-aminoquinolines, e.g. hydroxychloroquine and/or camostat - use of hydroxychloroquine, chloroquine and or camostat within 6 months prior to baseline - patients with known retinopathy or macular degeneration patients with known glucose-6-phosphate dehydrogenase (g6pd) deficiency - prolonged qtc-interval in baseline ecg (>500 ms) - concomitant medication associated with qtc-interval prolongation, which cannot be withdrawn prior to study drug administration - major comorbidities, possibly leading to increased unwanted side effects of study drugs: